NHC
National HealthCare Corporation
NHC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NHC overall, supported by stronger modeled upside and stronger valuation.
NHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
NHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $88.68 | -58% |
| Fair | 22x | $156 | -26% |
| Current | 29x | $211 | — |
| Expensive | 33x | $242 | +15% |
Historical ranges are pointers, not guarantees.
NHC's PE is in its expensive range at 29x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NHC in the historical PE scenario, which offers more potential upside but is not a forecast.
NHC Forward outlook
There aren't enough analyst estimates for NHC to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $7.24 | +12% |
| Q2 2026 | $8.89 | +33% |
| Q1 2026 | $7.87 | +14% |
| Q4 2025 | $7.67 | +17% |
| Q3 2025 | $6.47 | -19% |
| Q2 2025 | $6.70 | +13% |
| Q1 2025 | $6.91 | +31% |
| Q4 2024 | $6.53 | +50% |
NHC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $408M | +6.6% |
| Q2 2026 | $408M | +8.8% |
| Q1 2026 | $381.8M | +2.2% |
| Q4 2025 | $386.5M | +4.6% |
| Q3 2025 | $382.7M | +12% |
| Q2 2025 | $374.9M | +25% |
| Q1 2025 | $373.7M | +26% |
| Q4 2024 | $369.4M | +23% |
NHC's revenue has grown year over year for 14 quarters in a row: $408M last quarter, up 6.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +2 points |
| Q2 2026 | 12% | +2.9 points |
| Q1 2026 | 8.4% | +0.2 points |
| Q4 2025 | 8.6% | +1.4 points |
| Q3 2025 | 7.9% | +1.8 points |
| Q2 2025 | 9.1% | +1.6 points |
| Q1 2025 | 8.2% | +3 points |
| Q4 2024 | 7.2% | +0.5 points |
NHC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $99.2M | +76% |
| Q2 2026 | $30.7M | -42% |
| Q1 2026 | $52.9M | +60% |
| Q4 2025 | $6.4M | +38% |
| Q3 2025 | $56.5M | +98% |
| Q2 2025 | $52.6M | +23% |
| Q1 2025 | $33.1M | +797% |
| Q4 2024 | $4.6M | -73% |
NHC generated $189M in free cash flow over the past year, up 29% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +101K shares |
| 1 year | +1.9% | +300K shares |
| 3 years | +4.2% | +640K shares |
| 5 years | +3.9% | +601K shares |
| Available history | +3.9% | +605K shares |
NHC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1M |
| Q2 2026 | $7.2M |
| Q1 2026 | $16.3M |
| Q4 2025 | $5.2M |
| Q3 2025 | $3.2M |
| Q2 2025 | $4.7M |
| Q1 2025 | $1.7M |
| Q4 2024 | — |
NHC spent $30M buying back its own shares over the past year, about three times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.5x | Very low |
NHC's net debt is about 2.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NHC on leverage, with a lower net debt burden relative to earnings.
NHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.0 | Neutral |
| Stochastic | 15.5 | Oversold |
NHC's weekly RSI is 50 (neutral) and its Stochastic is 15 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NHC PE vs Healthcare Sector
| Metric | NHC | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 26x | 13% above |
| PE % | 73 | 29 | 44 pts above |
NHC is trading at 29x earnings, a 13% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NHC on valuation relative to its sector.
NHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $223.3 | 5.6% below |
| 20 week MA | $222.8 | 5.4% below |
| 50 week MA | $188.1 | 12% above |
| 100 week MA | $147.3 | 43% above |
| 200 week MA | $117.5 | 79% above |
NHC has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 79% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NHC on trend strength, trading above more of its moving averages.
NHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.0 | $66.3 | -22% |
| 2021 | $66.3 | $67.7 | +2.2% |
| 2022 | $67.7 | $61.8 | -8.8% |
| 2023 | $61.8 | $92.4 | +50% |
| 2024 | $92.4 | $109.6 | +19% |
| 2025 | $109.6 | $138.7 | +27% |
| 2026 YTD | $138.7 | $210.8 | +52% |
NHC has finished higher in four of the last six years. It's up 52% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NHC on returns for 2026, with the stronger performance.